[Evaluation of E-221-005 in inflammatory nasal diseases by double blind metod].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005069:Evaluation Studies as Topic; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008875:Middle Aged; D009113:Muramidase / Q000627:therapeutic use*; D009278:Naphazoline / Q000627:therapeutic use; D009281:Naphthalenes / Q000627:therapeutic use*; D014663:Nasal Decongestants / Q000627:therapeutic use*; D010919:Placebos; D012220:Rhinitis / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D004338:Drug Combinations; D007093:Imidazoles; D009281:Naphthalenes; D014663:Nasal Decongestants; D010919:Placebos; D009113:Muramidase; D009278:Naphazoline